ArticleUgeskrift for laeger2007
[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes].
Article in Ugeskrift for laeger, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Intracellular C3 protects β-cells from IL-1β-driven cytotoxicity via interaction with Fyn-related kinase.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Article
- The role of modulators in cystic fibrosis related diabetes.Journal of clinical & translational endocrinology · 2022Article
- Regulated Cell Death Seen through the Lens of Islet Transplantation.Cell transplantation · 2018Review
- Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition.World journal of diabetes · 2015Review
- Insulin signalling mechanisms for triacylglycerol storage.Diabetologia · 2013Review
- Expanding the clinical indications for α(1)-antitrypsin therapy.Molecular medicine (Cambridge, Mass.) · 2012Review
Corrections and comments
- Reprint of
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
Identifiers
18031661W2413455967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.